Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
About PAH
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

About PAH

Pulmonary arterial hypertension (PAH) is a devastating disease. Before the introduction of modern therapies, on average, patients survived only 2.5 years.1 Fortunately, treatment options have expanded over the last decade and now include 6 FDA-approved medications. With these expanded treatment options, the prognosis is improving2 and patients are living longer than historical predictions indicated. PAH therapies, including Ventavis® (iloprost), have had a positive impact on clinical status, exercise capacity, functional class, and hemodynamics.

Pulmonary Arterial Hypertension Defined

Mean pulmonary artery pressure (mPAP) ≥ 25 mm Hg with a pulmonary capillary wedge pressure ≤ 15 mm Hg measured by cardiac catheterization1

Read more about Ventavis:

  • Disease Classification

    • 1. Badesch DB, Abman SH, Simonneau G, Rubin LJ, and McLaughlin, V V. Medical Therapy for Pulmonary Arterial Hypertension. Chest 2007;131:1917-1928.
    2. Chin KM, Rubin LF. Pulmonary Arterial Hypertension. J Am Coll Cardiol 2008;51:1527-38)


    * In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

    IMPORTANT SAFETY INFORMATION:
    In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

    Please see full Prescribing Information

    For more information about
    Ventavis, please call
    1-866-ACTELION (1-866-228-3546).

    Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

    THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
    SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
    ©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

    		ACTELION